Highlights of Contemporary Genetically Altered Models may be contributed or invited and is meant to acquaint toxicologic pathologists with important biological and morphological features of newly established transgenic, knock-out, and related genetically engineered animal models. Although these Highlights will be based upon previously published papers, submissions will be peer reviewed. Suggested format includes background; experimental approach; biological, clinical, and pathologic (lesions, pathogenesis, and histomorphology) features; applications and implications.
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BACKGROUND
The estrogen receptor (ER) appears to be important in the regulation of many processes during embryonal and fetal development, control of reproduction and reproductive behavior, normal physiologic functions, and cancers affecting the reproductive tract in humans. The ER is a nuclear protein and a member of the steroid receptor superfamily. It functions as ligand-activated transcription factor through its interaction with estrogen, a steroid hormone that elicits distinct effects on specific cells and target tissues. In the uterus, estrogen acting via the ER has a trophic effect, resulting in increased RNA synthesis, protein synthesis, DNA synthesis, mitosis, and hyperplasia (6, 7) . In the anterior pituitary estrogen has a suppressive effect on follicle-stimulating hormone and luteinizing hormone production, but causes increased synthesis and secretion of prolactin (9) . Nontraditional target sites of estrogen are bone (3) and the cardiovascular system (1). To date, the exact role of estrogen and the ER in nontraditional target tissues is not known. This paper highlights a line of transgenic mice in which the ER gene has been disrupted through homologous recombination techniques resulting in an ER gene mutant (ER knockout or ERKO) mouse.
EXPERIMENTAL APPROACH
In generating the ERKO mice, the ER gene was disrupted by insertion of a 1.8 kB PGK-Neomycin sequence into exon 2, approximately 280 bp downstream of the transcription start codon (4, 5) . The Neomycin insert inhibited proper transcription and translation of the ER gene and hence protein expression through the inclusion of premature stop codons and polyadenylation sequences.
The disrupted ER gene was successfully transmitted in the germ cell line of a mouse that produced heterozygous mice of both sexes. Heterozygotes were defined as mice containing 1 copy of the wild-type ER gene and 1 copy of the inactivated gene. The heterozygotes were fertile and showed no overt phenotype in association with the disrupted ER genotype. Crosses of the heterozygotes resulted in offspring with Mendelian genotypes that were wild type, heterozygotes, or homozygous ER mutants.
Sex determination was not affected in ER mutants, and disruption of the ER did not appear to be lethal (4) . Both sexes of the homozygous ER mutant mouse were found to be infertile but survived to adulthood with no abnormal external phenotypes.
BIOLOGICAL, CLINICAL, AND

PATHOLOGIC FEATURES
The ERKO females have uteri that are grossly reduced in size and lack responsiveness to estrogen treatment (4, 5) . Western blot analysis of uterine preparations in ERKO females show no detectable full-length or truncated ER protein, whereas heterozygotes have one-half the concentration of ER protein than that of the wild-type females (5) . ERKO females treated with the estrogen agonists estradiol, DES, or hydroxy tamoxifen did not show the characteristic increase in uterine size and weight typically observed following estrogen treatment, although this observation was seen in wild-type females (4). Histologically, uteri from ERKO mice contain hypoplastic endometrial glands, stroma and myometrium (5) (Fig. 1 ). This morphology is unaltered after administration of estrogen.
Histologically, the ovaries from ER mutants typically have large hemorrhagic cysts and a few preovulatory follicles but no functional corpora lutea, although granulosa and theca cells are present (4, 5) (Fig. 2 ). The hormonal pattern in ERKO females is similar to hormone levels in humans with polycystic ovary syndrome; however, histologically, the lesion observed in the ERKO phenotype is different from that seen in humans (5, 8) .
The ERKO mammary gland phenotype is similar to that observed in immature wild-type females. Other organs affected in ERKO mice include liver and bone (5) .
The testes of male ERKO mice are characterized by reduced size and intact seminiferous tubules that are highly dysmorphic and contain few germ cells (4) ( 3). Although sperm may be observed in the testes and epididymis, sperm counts are usually less than 10% of those in wild-type males. There is 1 documented clinical case of a fully masculinized human male patient shown to be insensitive to estrogen as a result of a mutated ER gene (4, 5) . It was found that the patient was homozygous for a mutation in exon 2 of the ER gene, resulting in the coding of a truncated form of the ER protein. The patient showed nonclosure of his epiphyses and decreased bone density, similar to that observed in ERKO mice (4, 5) . APPLICATIONS AND IMPLICATIONS The ERKO mouse model will serve a role in ascertaining the importance of the ER in the mediation of normal physiologic functions, reproduction, fetal and embryonal development, and cancer. The ERKO male mice will be helpful in our understanding of the function of the ER in male reproductive biology, physiology, and pathology. The ERKO mouse is an excellent model for examining &dquo;cross-talk&dquo; mechanisms between steroid hormone and growth factor receptor signaling pathways (2) .
